Compare AstraZeneca plc (AZN) vs Unilever plc (UL) Price & Performance

AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).

The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.

Unilever (UL) trades at $62.96, down 1.1% over 24 hours, with technical indicators showing a bullish trend and strong support at $62. The company reported $50.5B revenue in 2025 with a net income margin of 18.75%, though recent quarters saw earnings misses. Positive sentiment is driven by a potential merger with McCormick and strong Q2 2026 volume growth, while analyst consensus is mixed with 24% buy ratings.

The outlook is cautiously optimistic due to merger synergies and margin expansion potential, but risks include integration challenges and competitive pressures. Cash flow volatility and debt levels warrant monitoring. The stock presents a value opportunity if execution improves, but near-term volatility may persist amid macroeconomic uncertainties.